Updated:
Cortexyme
Cortexyme is a San Francisco-based entity with no disclosed AUM, leadership, or investment activity, classified as a biotech-focused firm in public...
Cortexyme
Cortexyme is classified in internal records as a San Francisco-based entity with an unspecified firm type, suggesting it may be a dormant corporate vehicle or an undocumented family office. Public filings and investment databases show no founding year, no named operators, and no disclosed capital — a blank slate that places it among the least visible firms in the Altss universe. The firm's nominal association with biotech and healthcare services is inferred from sector tagging, but no confirmed portfolio companies, patents, or clinical trials link back to the entity itself. Without a scraped website, LinkedIn presence, or press coverage, Cortexyme's strategy and deployment model remain entirely opaque. No asset-class mix, stage preference, or co-investment activity has been reported. The lack of any named deals or co-investors precludes geographic or sector specificity beyond its California headquarters. Team size, adjacent vehicles like philanthropic foundations or real-asset arms, and any recent operational events are undocumented. The firm has not been involved in any publicly recorded transaction or hiring activity in the last 24 months. The structural differentiator, if any, is the mystery itself: a San Francisco entity with neither a web footprint nor a public investment record may serve as a shell company, a single-family office for an undisclosed individual, or a firm that has dissolved without formal notice. Its classification as a DB entity with no further detail is itself an anomaly worth monitoring.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
What is Cortexyme's investment focus?
Cortexyme is tagged with biotech and healthcare services in Altss records, but no public documents, website, or deal history confirm any active investment strategy. The firm may be a dormant legal entity rather than an operating family office.
Who runs investment decisions at Cortexyme?
No named principals, CIOs, or investment committee members are publicly recorded for Cortexyme. The firm's leadership structure is entirely undocumented, which is unusual even for a private family office.
Is Cortexyme a single family office or a different type of firm?
The firm type is unspecified in public records. Its San Francisco location and lack of institutional presence suggest it could be a single-family office, an inactive corporation, or a holding company without operational activity.
Does Cortexyme participate in fund commitments or direct deals?
No evidence of either fund commitments or direct investments exists in any public database or press source. The firm's capital deployment activity, if any, has not been reported.
Where does Cortexyme's underlying wealth come from?
The origin of any associated wealth is not disclosed. No family name, founder, or source of capital has been linked to Cortexyme in public records.
How can allocators learn more about Cortexyme?
Without a website, LinkedIn profile, or media coverage, allocators would need to rely on private records or direct outreach. The firm's lack of public visibility poses challenges for due diligence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: